Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy

NCT01466595 is registered in ClinicalTrials.gov with Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections as lead sponsor.

NCT NCT01466595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01466595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2011
Completion date
November 30, 2012
Enrollment
73 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1 infection